CD19 and diffuse large B-cell lymphoma: Clinical trials of CAR T cell-targeting CD19 have shown significant responses in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL) etc. [3,4,5,6,7,8,9,10,11].